Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.58 and traded as high as $0.61. Protagenic Therapeutics shares last traded at $0.57, with a volume of 22,910 shares changing hands.
Protagenic Therapeutics Stock Down 3.4 %
The business's fifty day moving average is $0.48 and its two-hundred day moving average is $0.58. The company has a market cap of $9.81 million, a P/E ratio of -2.59 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
Get
Protagenic Therapeutics alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share for the quarter.
Institutional Investors Weigh In On Protagenic Therapeutics
A hedge fund recently raised its stake in Protagenic Therapeutics stock. Renaissance Technologies LLC grew its holdings in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 102,200 shares of the biotechnology company's stock after purchasing an additional 41,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.47% of the company's stock.
About Protagenic Therapeutics
(Get Rating)
Protagenic Therapeutics, Inc operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations.
Read More
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.58 and traded as high as $0.61. Protagenic Therapeutics shares last traded at $0.57, with a volume of 22,910 shares changing hands.
Protagenic Therapeutics, Inc.（OTCMKTS: PTIX — Get Ratinge）的股价在周一的交易中突破了其两百天移动平均线。该股的两百天移动平均线为0.58美元，交易价格高达0.61美元。Protagenic Therapeutics股票最后一次交易价格为0.57美元，成交量为22,910股易手。
Protagenic Therapeutics Stock Down 3.4 %
Protagenic Therapeutics 股票下跌
The business's fifty day moving average is $0.48 and its two-hundred day moving average is $0.58. The company has a market cap of $9.81 million, a P/E ratio of -2.59 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
该公司的五十天移动平均线为0.48美元，其两百天移动平均线为0.58美元。该公司的市值为981万美元，市盈率为-2.59，beta值为0.06。该公司的债务与权益比率为0.04，速动比率为14.93，流动比率为14.93。
Get
Protagenic Therapeutics
alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share for the quarter.
Protagenic Therapeutics（OTCMKTS: PTIX — Get Rating）最后一次公布其季度收益数据是在11月14日星期一。这家生物技术公司报告了本季度每股收益（0.05美元）。
Institutional Investors Weigh In On Protagenic Therapeutics
机构投资者对 Protagenic Therapeutics 表示关注
A hedge fund recently raised its stake in Protagenic Therapeutics stock. Renaissance Technologies LLC grew its holdings in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 102,200 shares of the biotechnology company's stock after purchasing an additional 41,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.47% of the company's stock.
一家对冲基金最近提高了其在Protagenic Therapeutics股票的股份。Renaissance Technologies LLC在向美国证券交易委员会提交的最新13F文件中显示，该公司在第一季度将其在Protagenic Therapeutics, Inc.（OTCMKTS: PTIX — 获取评级）的持股量增加了69.2％。该机构投资者在本季度又购买了41,800股股票后，拥有该生物技术公司的102,200股股票。在最近一个报告期结束时，Renaissance Technologies LLC拥有Protagenic Therapeutics约0.59％的股份，机构投资者和对冲基金拥有该公司3.47％的股票。
About Protagenic Therapeutics
Protagenic Therapeutics, Inc operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations.
Protagenic Therapeutics, Inc是一家生物技术公司。它从事治疗压力相关疾病的疗法的发现和开发，包括创伤后应激障碍、抑郁症、焦虑以及药物和酒精成瘾。该公司提供基于 PT00114 肽的配方。
Read More
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 免费获取 StockNews.com 关于 Protagenic Therapeutics (PTIX) 的研究报告
- 为什么黄金现在可以成为你投资组合的闪亮补充
- SoFi Technologies 打破收益但要当心美联储
- 买入 Colgate-Palmolive 的 Dip
- Mullen Automotive 正在疯狂招聘，那可能意味着什么？
- InterDigital 上调了收益预期
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Protagenic Therapeutics 的新闻和评 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Protagenic Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
